Summary
Johnson & Johnson (JNJ) announced on November 3, 2020, a significant development regarding ongoing talc litigation. The Missouri Supreme Court declined to hear the company's appeal of the "Ingham verdict," which had previously been reduced from $4.7 billion to $2.1 billion. This decision means JNJ will now record a reserve of approximately $2.1 billion (excluding interest) in its fiscal year 2020 year-end results to account for this specific verdict.
Key Highlights
- 1Missouri Supreme Court declined to hear JNJ's appeal of the "Ingham verdict" related to talc cases.
- 2The original verdict of $4.7 billion was previously reduced to $2.1 billion by the Missouri Court of Appeals.
- 3JNJ will record a reserve of approximately $2.1 billion (excluding interest) in its 2020 fiscal year-end results.
- 4The company intends to continue challenging the verdict by petitioning the United States Supreme Court for review.
- 5This event relates to the ongoing talc litigation that has been previously disclosed by the company.
Frequently Asked Questions
The "Ingham verdict" is a legal judgment related to certain talc cases against Johnson & Johnson. It was originally set at $4.7 billion but was reduced to $2.1 billion by the Missouri Court of Appeals. The Missouri Supreme Court's decision not to hear JNJ's appeal makes this $2.1 billion judgment a concrete liability that the company will reserve for in its financial statements.
Johnson & Johnson will record a reserve of approximately $2.1 billion (excluding interest) in its fiscal year 2020 year-end results to cover this verdict. This will directly affect the company's reported earnings and financial position for that period.
No, the company stated that it will continue to challenge the Ingham verdict by petitioning the United States Supreme Court for review. This indicates that the legal process is still ongoing, though the immediate financial impact of the Missouri Supreme Court's decision is to establish the reserve.
The filing specifies that this reserve is "consistent with the Ingham verdict." It is not explicitly stated whether this covers all talc-related liabilities. Investors should refer to JNJ's other SEC filings, particularly the 10-Q, for a comprehensive understanding of the company's total exposure to talc litigation.